Generated by AI
Genmab A/S American Depositary Shares represents ownership in Genmab A/S, a Denmark-based biotechnology company focused on developing antibody-based therapies. The company’s business centers on human antibody therapeutics for cancer and other serious diseases, with products and product candidates spanning oncology and selected additional therapeutic areas. Its portfolio includes approved and partnered medicines, as well as research programs built around proprietary antibody technologies such as DuoBody and HexaBody. Genmab works across discovery, development, and commercialization, collaborating with pharmaceutical partners to advance biologic treatments through the clinical and regulatory process. The company serves the global biopharmaceutical market and plays a role in supplying innovative immunotherapy and antibody platforms to healthcare providers and patients worldwide.
WebsiteCarl Jacobsens Vej 30
Copenhagen, 2500
Denmark
The latest articles about GMAB.
Company Announcement COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 164,828 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,961 shares at DKK 1,362.5,17,676 shares at DKK 1,615,949 shares at DKK 1,948,25,635 shares at DKK 2,070,6,1
Summary of Oct 30's posts. Generated by AI.
Summary of Oct 29's posts. Generated by AI.
Summary of Sep 29's posts. Generated by AI.
Summary of Oct 30's posts. Generated by AI.
Investors talking about GMAB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.